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 ABSTRACT 
TITLE : “RELEVANCE OF SERUM BNP LEVEL IN THE STUDY OF 
HEART FAILURE WITH PRESERVED EJECTION FRACTION AT 
TERTIARY HOSPITAL” 
INTRODUCTION : Heart failure with preserved ejection fraction (HFpEF) is 
becoming a more common diagnosis as the prevalence of patients with hypertension, 
diabetes and advancing age increases. HFpEF is now the cause of clinical heart 
failure in approximately 50% of patients, a frequent cause of hospitalization, and is 
associated with significant morbidity and mortality. In addition to clinical 
assessment, the severity of heart failure is assessed by measuring B-type natriuretic 
peptide (BNP), a peptide hormone released by cardiomyocytes in response to 
increased wall stress in patients of HFPEF”. It is planned to study all such cases of 
HFpEF (diagnosed with ECHO) and relevance of raised brain type natriuretic 
peptide (BNP) levels with that. 
OBJECTIVE : “To study the relevance of serum B type Natriuretic peptide levels 
in patients presenting with acute left heart failure with preserved ejection fraction”. 
METHODS: 50 patients presenting in Emergency Department (ED) or Inpatient 
Department (IPD) and Intensive care unit (ICU) with diagnosis of Diastolic 
dysfunction were taken in this study. Detailed 2D Echo, BNP levels along with 
routine blood samples were taken. The study took place for a period of 18 months. 
Statistical analysis was done using Percentage, Standard error of  proportion and 
chi-square test. 
 RESULTS: In present study 50 HFPEF patients were taken whose mean age group 
was 63.60 years and majority of the patients were female (62%) and were  
overweight with mean BMI of 25.24 Kg/m2 and  had associated comorbidities in the 
form of hypertension (68%), diabetes mellitus (62%). In the present study, BNP 
levels were higher in majority of the patients with significant association to all the 
parameters like age, sex, comorbidities,  LA size (p - 0.001), Diastolic Dysfunction 
type (p – 0.033)  and NYHA grade. 
CONCLUSION: The present study of 50 cases of HFPEF was aimed at 
highlighting BNP relevance  in HFPEF patients with in terms of age & sex 
distribution, vital parameters, laboratory parameters, comorbities, M- mode 
echocardiography, NYHA class, Diastolic dysfunction type at the time of 
presentation. Thus, focus should be on monitoring diastolic disease progression in 
the preclinical phase and prevention of heart failure hospitalization. Thus, studies 
should be done to identify patients who may benefit from closer surveillance and 
tighter control of their risk factors. 
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INTRODUCTION 
Heart Failure is defined as a syndrome characterized by an impaired ability of the 
heart to fill with and/or to eject blood commensurate with the metabolic needs of the 
body, resulting in a classic constellation of signs or symptoms of pulmonary and systemic 
venous congestion.1 
Heart failure is defined as a complex clinical syndrome that results from 
structural or functional impairment of ventricular filling or ejection of blood, which in 
turn leads to the cardinal symptoms of dyspnea and fatigue and signs of HF, namely 
edema and rales.2 Heart failure (HF) affects about 2% of the western population, with 
the prevalence increasing sharply from 1% in 40-year-old individuals to 10% above 
the age of 75 years. It is the most common cause of hospitalization in patients over 65 
years of age.1,3,4 It is a debilitating condition with frequent hospitalization with a very 
high mortality rate with economic and public health burden. Heart failure once 
thought to arise primarily in the setting of depressed left ventricular (LV) ejection 
fraction (EF). However, epidemiologic studies have shown that approximately one-
half of the patients who develop heart failure (HF) have a normal or preserved 
ejection fraction (EF>50%).5 
Heart failure with preserved ejection fraction (HFpEF) is becoming a more 
common diagnosis as the prevalence of patients with hypertension, diabetes, chronic 
kidney disease (CKD) and advancing age increases. HFpEF is now the cause of 
clinical heart failure in approximately 50% of patients, is a frequent cause of 
hospitalization, and is associated with significant morbidity and mortality. The 
diagnosis of HFpEF depends on the clinical diagnosis of heart failure in the setting of 
Introduction 
 
	 	2	
 
preserved ejection fraction, usually with an ejection fraction 45%.6 In addition to 
clinical assessment, the severity of heart failure is often assessed by measuring B-type 
natriuretic peptide (BNP), a peptide hormone released by cardiomyocytes in response 
to increased wall stress.7  
The most useful and gold standard method for diagnosing heart failure is 
echocardiography. The main disadvantages of echocardiography are 
 In patients who are obese and have concomitant chronic lung disease with 
respiratory distress echocardiography is ineffective. 
 It is more difficult to diagnose heart failure in patients who are having normal 
ejection fraction . 
Because of these disadvantages biochemical markers are used for accurate 
diagnosis and prognosis of heart failure by clearly determining its incidence and 
stage.8 B-type natriuretic peptide (BNP)is the most commonly used laboratory test 
because its clinical usefulness in diagnosis and prognostic rating of heart failure is 
proven in large number of studies.9,10 To address this problem, this paper focuses on 
the significance of BNP in patients with heart failure. 
BNP is a substance secreted from the ventricles or lower chambers of the heart 
in response to changes in pressure that occur when heart failure develops and 
worsens. The level of BNP in the blood increases when heart failure symptoms 
worsen, and decreases when the heart failure condition is stable. The BNP level in a 
person with heart failure even someone whose condition is stable is higher than in a 
person with normal heart function.11 Signs or symptoms of congestive heart failure 
include lung crepitations, pulmonary oedema, ankle swelling, hepatomegaly, 
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dyspnoea on exertion, and fatigue. Different modes of presentation of dyspnea (i.e. 
effort related or nocturnal) need to be distinguished.12 In HFNEF, breathlessness is 
frequently the earliest symptom due to pulmonary congestion.13 
The management of heart failure with diastolic dysfunction is not well defined 
than the management of heart failure with systolic dysfunction and remains a 
challenge. Hence the need for study. It is planned to study all such cases of HFpEF 
(diagnosed with ECHO) and relevance of raised brain type natriuretic peptide (BNP) 
levels with that. This study is likely to make available a variety of information 
(especially ECHO and clinical data) that should better characterize the syndrome of 
diastolic dysfunction and hopefully provide directions and to plan its better 
management. 
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AIMS AND OBJECTIVES 
The aim of the present study was as follows:- 
 To study the relevance of serum B type Natriuretic peptide levels in patients 
presenting with acute left heart failure with preserved ejection fraction. 
Review of Literature 
 
	 	5	
 
REVIEW OF LITERATURE 
Diastole means ‘expansion’ in Greek and includes the part of the cardiac cycle 
starting at the closure of AV valve, when the pressure in LV falls below aortic 
pressure and finishing at the closure of mitral valve. A normal LV diastolic 
dysfunction may be clinically defined as the capacity of the left ventricle to receive a 
LV filling volume able in its turn to guarantee an adequate stroke volume, operating 
at a low pressure regimen. Diastole or relaxation is the process whereby the 
myocardium returns after contraction to its unstressed length and force. It related to 
the processes underlying ca2+ extrusion from the cytosol and cross bridge detachment. 
As a vitality expending process, anomalous LV active relaxation is either due to 
cardiac ischemia or abnormalities in myocardial energy metabolism.14  
Diastole is a complex process which is influenced by various factors such as 
ischemia, heart rate, velocity of relaxation, cardiovascular consistency, left ventricular 
hypertrophy and segmental wall coordination of the heart muscle. The term diastolic 
dysfunction refers to abnormal mechanical (diastolic) properties of the left ventricle. 
It demonstrates abnormal distensibility of diastole, filling or LV relaxation/ 
compliance and increased LV passive stiffness that alters the ease with which blood 
flows despite of whether the EF is preserved or abnormal or whether the patient is 
symptomatic or asymptomatic. 
When diastolic dysfunction becomes symptomatic i.e. when dyspnoea occurs - 
diastolic heart failure occurs. Diastolic dysfunction may be present several years 
before any symptoms occur and may represent the first phase of diastolic heart failure. 
Asymptomatic diastolic dysfunction manifested by severe LVH and/or abnormal echo 
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parameters is frequently found in hypertension and ischemic heart disease. Although 
many such patients remain asymptomatic for some time, there is a clear relationship 
between diastolic functional abnormalities and long term hospital admissions for HF. 
Patients of HFPEF are characterized more often with a non dilated LV, concentrated 
LVH or atleast concentric LVH remodelling and normal LVEF. A comparison of 
endomyocardial biopsies revealed higher cardiomyocytes diameter and higher 
myofibrillar density in patients with HFPEF compare with those with HF and 
impaired LVEF. 15 
HFPEF has impaired DD due to concentric remodelling of the heart along with 
impaired LV compliance and with increased substrate of LV stiffness which is due to 
deposition of type 1 collagen which results in a stiff and noncompliant ECM.16 Now 
recent, studies are being focusing on oxidative stress, inflammation endothelial 
dysfunction along with molecular cell level disorder that impairs nitric oxide- cyclic 
guanosine monophosphate (cGMP) -protein kinase G (PKG) signaling pathways 
which are thought to have a role in patients with HFPEF. 17 
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FIG: 1 Prognostic importance of changes in cardiac structure and function in 
patients with HFpEF. A- Left atrial enlargement,  B -Diastolic Dysfunction type,  
C - LV hypertrophy 18 
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FIG: 2 Mechanisms of increased LV diastolic pressure. 
 There are 4 patterns of DPVR (Diastolic pressure volume relationship) can be 
found out in patients with heart failure and increased LV diastolic pressure. 
 DPVR in patients with HFpEF may be described by graphed curves A to C.  
In curve A, the relaxation is prolonged and LV diastolic pressure reduced 
throughout diastolic but remains increased. 
Curve B is the most prevelant pattern in HFPEF and in this DPVR shifting 
upwards and to left, indicating reduced distensibility, where LV pressure is increased 
at any LV volume.  
In curve C, there is an upward parallel shift in DPVR due to pericardial 
constraint. 
Curve D indicated DPVR in patients with HFrEF. In that curve there is 
eccentric remodeling which leads to right side shift of DPVR due to increased 
distensibility. It is clear that even the ventricle is distensible, there is high end 
diastolic volume and also end-diastolic stiffness is high.19 
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ETIOLOGY OF PRESERVED EJECTION FRACTION( >40-50%) 20 
1. Pathologic Hypertrophy-  
 Primary (Hypertrophic Cardiomyopathies) 
 Secondary (Hypertension) 
 Aging 
2. Restrictive Cardiomyopathy 
 Infiltrative disorders (Amyloidosis, Sarcoidosis) 
 Storages diseases (haemochromotasosis) 
 Fibrosis 
 Endomyocardial disorders 
Hypertension, Diabetes and Cardiac ischemia are the most common causes of 
Heart Failure with Normal ejection Fraction. 21 
Prevalence of hypertension : 83% approximately 
Prevalence of Diabetes : 30% approximately 
Prevalence of CAD : 40 - 50% approximately 
Impairment of diastolic dysfunction appears to be age related and multiple 
studies have shown that 10% of patients with HF below the age of 50 years have 
diastolic dysfunction and this rises up to 70% in patients aged over 80 years. 22 
Diastolic dysfunction has been shown to affect geriatric women more than any other 
population subgroup. 
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Consistent with the burden associated with HFPEF, the prognosis of patients 
with HFPEF also appears to be marginally better than that of HFREF. Recent studies 
showed that deaths which are not related to cardiac causes are higher in patients with 
HFPEF as compared to patients with HFREF, and it could be a due to the multiple 
complicity of the diseases in patients with HFPEF.23 
Data is very limited regarding the heart failure prevalence and incidence 
depending upon the EF and how it had changed over time. In cross-sectional studies, 
the proportion of patients with preserved ejection fraction ranges from 40-70% with 
an average of about 50%.24 Doppler echocardiography and tissue Doppler 
echocardiographic techniques show that almost 30-50% patients with symptomatic 
HF have a relatively normal or preserved ejection fraction but are associated with 
abnormalities of compliance, stiffness and relaxation. The mortality rate of heart 
failure with diastolic dysfunction is as high as that of systolic dysfunction. Reported 
annual mortality rates for patients with diastolic dysfunction vary from 5.2% to 17.5% 
compared with 15-20% for patients with systolic dysfunction. 25 
The prevalence of HFPEF has shown an increment in the last 15 years but 
mortality remains unchanged by this disorder. These patterns underscore the 
significance of this developing general medical issue and the pressing need to 
characterize particular treatment for this element. 24 
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FIG :3 Prevalence of heart failure–related hospital admissions in patients with 
HFpEF.  
A, From 1987 to 2001,the number of patients with HFPEF form of heart 
failure is increased indicating that its prevalence continues to increase. This graph 
shows the percentage of number of patients with HFPEF form of heart failure.  
B, In this same 15-year , there is stable/ slightly downward trend in 
hospitalizations of patients with HFrEF but HFpEF patients, the number increasing 
significantly.26 
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Diastolic dysfunction on the basis of history, clinical examination, ECG, chest 
radiographic findings is difficult to differentiate it from systolic dysfunction. 
Therefore, objective diagnostic testing with cardiac catheterization, Doppler 
echocardiography, and possibly measurement of serum levels of B-type natriuretic 
peptide is often required. Worsening stages of DD on 2Decho are associated with 
increased risk of adverse outcomes such as development of clinical HF. 27 BNP and 
NT-proBNP levels were found to be closely related to the severity of diastolic 
dysfunction. 28 
 
FIG 4: VARIOUS MARKERS OF CARDIAC STRESS 
In response to changes in the pressure as in heart failure, Brain Type 
Natriuretic Peptides is secreted from the ventricles which is a polypeptide. BNP level 
is directly proportional to severity of heart failure. As the heart failure sympotoms 
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worsens BNP level increases and it decreases when the condition is stable . So BNP is 
used for the assessment of severity of heart failure. 
BNP is a 134-amino acid preprohormone (preproBNP). It is encoded by the 
gene NPPB. Removal of the 25-residue N-terminal signal peptide produces the 
prohormone, proBNP, which is an O-linked glycoprotein and is stored intracellularly. 
With the help of a specific convertase (probably furin or corin) ProBNP is cleaved 
between arginine-102 and serine-103 into NT-proBNP and the biologically active 32-
amino acid polypeptide BNP-32.They are secreted into the blood in equal amounts.29 
Cleavage at sites other than this produces shorter BNP peptides with unknown 
biological activity.30 Processing of proBNP may be regulated by O-glycosylation of 
residues near the cleavage sites.31 
BNP was first discovered in the porcine brain that’s why it is named as brain 
natriuretic peptide. Later, it was discovered that in response to hemodynamic stimuli 
like ventricular volume expansion and pressure overload BNP is secreted from left 
ventricular myocardium. 32 BNP is cleaved into biologically active BNP C- terminal 
and the biologically inactive, NT-proBNP. 
 Then pro BNP enters into the circulatory system. ProBNP is the better 
diagnostic tool for ventricular dysfunction because it is secreted from the ventricles 
due to ventricular hemodynamic changes. 33 BNP causes :  
 Strong vascular relaxation  
 Natriuresis. 
BNP does not causes changes in normal heart, but atrial natriuretic peptide 
(ANP) will cause changes. This is due to the increased production and secretion of 
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BNP in response to increased hemodynamic changes.34 Neurohormonal theory 
explains main mechanism of heart failure; in view of this theory, BNP level increases 
because of the activation of natriuretic peptide system. This system acts as a counter-
regulatory system and it counteract the impaired neurohormonal balance in response 
to activation of the systems that induce vascular spasms (sympathetic nervous system, 
endothelin system and renin-angiotensin system,). Therefore, BNP is reported to 
indicate ventricular dysfunctions more efficiently than other NPs.35 
 
FIG : 5 MECHANISM OF FORMATION OF BNP 
Physiological effects of BNP: 
 Diuresis 
 Natriuresis  
 Vasodilator effects of the renin–angiotensin– aldosterone system (RAAS)  
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 Inhibition of the the sympathetic nervous system (SNS)  
 Vasodilation36  
Functions of NP system: 
 In CVS- control of homeostasis and its functions via co-ordinated central and 
peripheral actions. 
  In Brain stem- NPs decrease the sympathetic tone 
  In the Hypothalamus -they decrease the secretion of arginine vasopressin and 
corticotropin;  
  In areas adjacent to the Third ventricle -NP system inhibit salt appetite and 
water drinking.37 
Now it is found that cardiovascular NPs plays an autocrine and paracrine role 
in the control of myocardial and vascular structure and function as well. 
 
FIG : 6 EFFECTS OF BNP ON VARIOUS ORGANS 
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In the systemic circulation BNP causes intracellular cGMP production with 
the help of natriuretic peptide receptor type A (NPR‐A).  
Through proteolysis by neutral endopeptidases and by binding to the 
natriuretic peptide receptor type C (NPR‐C) BNP is removed from plasma. But NT‐
proBNP is mainly removed by renal excretion. NT pro BNP serum values are 6 times 
higher than BNP this is because of the difference in the half lives. Half‐life of BNP is 
20 mins and NT‐proBNP is 120 mins. Even though both molecules are released in 
equal proportion the difference in the half life are the reason for difference in serum 
levels.38 
 
FIG : 7 B-type natriuretic peptide (BNP) synthesis, release and receptor 
interaction. In cardiomyocytes BNP is produced as a prohormone. After the 
release into the circulation proBNP is divided into BNP and the N-terminal 
fragment (NT-proBNP) in equal proportions. Increase in the intracellular cGMP 
level is due to the association of BNP and the natriuretic peptide receptor type A 
(NPR-A). 
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FIG : 8 - Physiological effects of B-type natriuretic peptide (BNP) and 
ventricular wall stress and BNP release is due to the volume or pressure 
overload.38 
 
FIG : 9 - PHARMACOLOGIC ACTIONS OF BNP 
BNP level is associated with severity of heart failure. In New York Heart 
Association functional classification the relation between BNP and heart failure 
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severity is clearly categorized. So BNP is an useful tool for predicting patients 
prognosis39 .The criterion for the diagnostic value of a diagnostic test is its predictive 
power, which plays a crucial role in the process of therapeutic decision-making. BNP 
is an independent factor for the prediction of incidence and mortality rates.40 BNP is 
believed as an important prognostic factor that should be considered in future clinical 
trials. 41 
 
FIG : 10 DIAGNOSTIC CRITERIA FOR HFpEF from the Heart Failure 
Society of America.42 
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HFPEF rises with age and commonly affects those older than 70 years. 43 A 
review of the ADHERE database44 has shown that, patients with HFPEF are elderly 
age group, female preponderance, and were hypertensive but less likely to have had a 
MI as compared to patients with systolic dysfunction. Other parameters were also 
studied in the form of various comorbid conditions and are also common which 
include obesity, CAD, DM, hyperlipidaemia and AF, which were same in comparison 
to patients with HFREF.45 These all additive changes in cardiovascular structure and 
function along with a normal human ageing process increases risk for the 
development of this type of HFPEF. 46-47 First among these are changes or alterations 
in the stiffness of the central conduit artery along with increase in the hypertrophy of 
the left ventricular, and there is shift toward dependence on filling of left ventricle by 
left atrium (LA), and resulting in progressive enlargement of LA. The changes related 
to ageing along with development of changes in the endocrine, renal, pulmonary, 
ANS (autonomic nervous system) 48-50 causes changes in salt and water handling 
capacity of the body and resulting in increased vulnerability to acute pulmonary 
oedema because of altered pulmonary capacitance along with change in the 
distribution of blood volume. 
European Society of Cardiology 51 in 2007 proposed a diagnostic criteria and 
said that haemodynamic and echocardiographic findings are key components for the 
diagnosing the patients of HFPEF. Firstly, Patients should have signs and symptoms 
for heart failure which is identified on the basis of Framingham criteria. Secondly, 
absence of depressed EF i.e. EF should be at least 50% in a non-dilated heart with a 
LVED volume of 97 mL/m2. Thirdly, objective measurements which are showing the 
presence of Left ventricular DD, that can either be demonstrated with Doppler 
echocardiography or with cardiac catheterization or by a biomarker i.e. BNP levels. In 
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spite of the fact that these criteria have expanded the specificity for which the 
conclusion of HFPEF is influenced, these criteria have been condemned. For instance, 
no information exists on the positive and negative predictive value of BNP and 
furthermore, in certainty few patients who are well compensated despite obvious 
symptoms of HF might not have increase in BNP levels52. Furthermore, in the 
Framingham Heart Study and Mayo clinic , it identified that BNP levels fluctuates 
according to sex and age of the patients so normal age- related and sex-related 
references value should be there before interpreting the BNP levels and making a 
diagnosis of HFPEF correctly.53 
Invasive measurement of LV filling pressures always remains the gold 
standard investigation technique for the diagnosis of HFPEF and ought to be 
considered in cases in which diagnosis is questioned. Cardiac catheterization is 
additionally valuable for diagnosing pulmonary hypertension, which is commonly 
seen in patients of heart failure with preserved ejection fraction (HFPEF) and might 
be related to both post capillary pulmonary venous hypertension 54-55 as well as pre-
capillary component of PAH.56 A recent area of interest is a decrease in the 
longitudinal component of LV systolic function (easier to measure by 2D echo).57 The 
lessening in the longitudinal part of LV systolic function is being compensated by a 
preserved circumferential, radial, and twist components that are important in helping a 
normal left ventricular ejection fraction.58-59 Regardless of whether this can help in 
identifying cases of HFPEF needs larger prospective trials and studies which are 
suspected of this entity. So non-intervention things like haemodynamic assessment, 
echocardiographic evaluation is to be done in patients who are suspected with 
HFPEF. Plasma biomarker estimation i.e. Brain natriuretic peptides levels may help in 
diagnosis but in doubtful cases, the need of invasive assessment ought to be 
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considered to make the diagnosis. Tissue Doppler imaging is a more up to the date 
system that can be utilized with transmitral Doppler in combination to decide the 
presence and severity of this type of heart failure with diastolic dysfunction. 
The most important indicator of diastolic function is to estimate the mitral 
inflow signal. By determining this signal we can assess the grade of diastolic 
dysfunction and also seen the individual pressure difference of atria and ventricles. 
This will help to assess any diastolic pressure difference in the chambers. This is 
assessed by checking any change in shape and velocity of the inflow Doppler signal. 
The most specific alteration seen is by checking the diastolic dysfunction during early 
and late filling time along with checking the rapidity of fall in velocity in early 
diastolic ( E- wave) and the time taken for ventricles to get filled after relaxation 
(IVRT).  
Grading of diastolic dysfunction can be represented as follows 60 
Grade I = the pattern of relaxation is impaired with normal filling 
pressure/elevated filling pressure 
Grade II = Pseudo normalized pattern 
Grade III = Reversible restrictive pattern 
Grade IV = Irreversible restrictive pattern 
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FIG : 11 - Evaluation of diastolic function is depend upon the left ventricular 
filling dynamics. 
This is determined by Doppler measurement of mitral valve flow velocity and 
tissue Doppler measurement of mitral annular velocity. In general early diastolic 
mitral flow velocity (E) and the mitral annular velocity (e′) are brisk and occur nearly 
simultaneously. The mitral E velocity is reduced with mild diastolic dysfunction 
(impaired relaxation pattern—grade 1) and is less than the late diastolic mitral flow 
velocity (A). The E deceleration time (DT) is increased. In severe diastolic 
dysfunction (grades 2 and 3), E is increased and the DT is reduced. In these condition, 
e′ is reduced and delayed relative to the mitral E.61 
In normal young subjects, Left ventricle elastic recoil is vigorous because of 
normal myocardial relaxation; so most of the filling is completed in early diastole. So, 
the E wave will be taller than A wave and the E/A ratio is usually 1.5 or higher, DT is 
160 to 240 milliseconds, E/e’ is less than 8. This vigorous relaxation can also be seen 
as active motion of the mitral annulus away from the apex during early diastole in 
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parasternal long- axis and apical four- chamber view. Filling does not start as soon as 
the systole ends. First in the ventricles pressure had to fall below the left atrial 
pressure and the time this happens is known as isovolumetric relaxation (IVRT) and is 
in between 50 milliseconds to 100 milliseconds. With normal myocardial relaxation, 
the longitudinal mitral annulus diastolic velocity pattern mirrors that of normal mitral 
inflow: early diastolic velocity (e′) is higher than late diastolic velocity (a′). Lateral 
annulus velocity is always higher (normal, >15 cm/sec) than septal e′. Thus e’ 
increases with exercise in healthy subjects so that E/e′ is similar at rest and with 
exercise (usually <8). So as the age increases there is fall in rate of myocardial 
relaxation and elastic recoil of left ventricle and the pressure in the left ventricles 
started declining and filling becomes slower producing a diastolic function pattern as 
that of diastolic dysfunction grade I. At about 65 years of age the E wave velocity 
approaches A velocity and at around 70 years of age group it is < 1. 
 
FIG : 12 - Normal pattern of diastolic filling: A-wave smaller than E-wave 
GRADE I DIASTOLIC DYSFUNCTION (mild dysfunction) - Impaired relaxation 
with normal filling pressure. 
An abnormal relaxation of the ventricle will impair early diastolic filling and 
the height of the E-wave will decrease and the pressure of atrium has to be high 
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enough to initiate filling. Thus, IVRT will rise to > 100 milliseconds, and the 
Deceleration Time will also be prolonged to ≥ 240 milliseconds. As less volume is 
moving into the LV during early filling stage so more blood will be accumulating in 
the later stages of atrial contraction so atrium has to conduct more blood and will take 
more time. A-wave will be larger than normal and will also be larger than the E-wave 
(E/A ratio < 1) and this impaired relaxation is known as diastolic dysfunction grade I. 
 
FIG : 13 - Disturbed relaxation: the A-wave is larger than the E-wave 
GRADE 2 DIASTOLIC DYSFUNCTION- Pseudo normal filling pattern/ Moderate 
DD 
Progressive DD will further lead to increase in left atrial pressure. And 
increased atrial pressure further raises the pressure gradient of the atrium and ventricle 
of the left side and there will be increase in force to fill the ventricle during early 
diastole. Thus the size of the E-wave in relation to that of A-wave will increase, and 
E/A ratio will again return in normal range type that is in between 1 to 1.5 millisecond 
and normal Deceleration time and IVRT and this picture will look very similar to that 
of “normal” diastolic function. That’s why this grading is also known as “pseudo 
normal” pattern and is known as grade II diastolic dysfunction. This pattern can be 
distinguished from normal one by performing Valsalva manoeuvre, by flow 
propagation time, e’ ratio and many more methods. 
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FIG :14 - Pseudo normal filling: the E-wave is larger than the A-wave 
GRADE 3 DIASTOLIC DYSFUNCTION- Reversible restrictive filling pattern  
In this , increase in the further filling pressure will raise the pressure difference 
between left sided atrium and ventricles will further increase in the E wave with 
subsequent shortening of A wave. So the E/A will be changed and will be ≥ 2. In 
some cases due to the increase pressure gradient between atrium and ventricle the A 
wave will become so small that it can’t be seen in echocardiography and in such cases 
the E/A ratio can reach ≥ 5. But also when the filling pressure becomes so high there 
will be abrupt filling of the ventricle and stoppage. So in these cases other parameters 
are assessed like IVRT interval which should be ≤ 70 millisecond, DT should be < 
160 milli seconds and E/e’ ratio more than 15 for diagnosing. 
 
FIG : 15 Restrictive filling pattern: the E-wave is more than twice the size of the 
A-wave 
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GRADE 4 DIASTOLIC DYSFUNCTION- Irreversible restrictive filling Pattern - 
This advanced form of diastolic dysfunction that is grade 4 differs from grade 
3 only by the fact that the restrictive pattern is not changed by Valsalva manoeuvre 
and is because the valsalva may not be adequate or filling pressure is too high to be 
altered by valsalva manoeuvre. 
As per European society of cardiology guidelines on the diagnosis of HFPEF 
recommends the exclusion of HFpEF in the setting of normal BNP level (<100 pg/ml) 
and in present study the values >100 pg/ml were taken as significant to make the 
diagnosis in patients of HFPEF with signs and symptoms of heart failure, LVEF > 
50% and the value of E/e’ in between 8 and 1562. 
Veldhuisen et al63 Studied in 615 patients about the prognosis in cases of 
HFPEF and HFREF and founded that BNP levels were less in patients with HFPEF 
than in patients with HF with reduced LVEF, but the prognosis of the patients who 
were having HFPEF is same as of those patients with reduced LVEF. 
Gottdieneret al 64 studied congestive heart failure outcomes in 5888 patients 
who were 65 years of age. Out of 5532 participants, 269 patients had congestive heart 
failure, out of which LVF was normal in 63%, borderline decreased in 15%, and 
grossly impaired in 22% and concluded that more deaths were reported from heart 
failure in patients with normal systolic function because LV function is normal than 
impaired in elderly persons with heart failure. 
Iwanaga Y et al65 in 2006 studied in 160 consecutive patients presenting with 
HF, and measured plasma BNP levels as well as 2D Echo and cardiac catheterization 
was also done. From echocardiographic and hemodynamic data Systolic and diastolic 
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meridional wall stress was also calculated and concluded that Left ventricular end 
diastolic pressure had significant correlation with BNP values, but the correlation 
between end diastolic wall stress and plasma BNP [p < 0.001] was more strong but as 
compared with Systolic Heart Failure and Diastolic Heart Failure, the BNP level was 
significantly higher in SHF (p < 0.001) and concluded that plasma BNP levels reflect 
EDWS of left ventricle, not only in patients with systolic dysfunction, but also in 
patients with DD. 
Lee DS et al studied66 in Framingham Heart study about the risk factors, 
clinical characteristics during the onset of HF and long-term survival in cases 
according to ejection fraction ≤45% in 314(59%) vs. >45% in 220(41%) and found 
that HTN, AF, female gender were more associated with HFPEF while in HFREF MI 
was most common cause. 
Bursi et al 67 studied the risk factors in 308 patients and found out that the 
patients with HFPEF are older(77%), hypertensive(86%), female gender(57%), mean 
BMI (29.6kg/m2), DM(36%), AF(31%), renal impairment(11%), hyperlipidaemia 
(38%), COPD(38%) and less likely to have CAD. 
Tsuchihashi-Makaya M et al68 compared the outcomes by using registry data 
base in Japan from 164 hospitals in 2675 patients who had mean follow up of 2.4 yrs 
in HFPEF vs. HFREF in view >50% in 429 subjects were more likely to be elderly, 
female gender, having HTN & Atrial Fibrillation, as compared with those with 
HFREF in 985 patients EF < 40 % in which ischemic cause was the likely etiology. 
The mortality in hospital and after discharge seen in patients of HFPEF group as 
compared to HFREF group was similar. 
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Devereux RB et al 69 studied CHF in a population based sample with normal 
systolic function. In this study 95 patients were taken out of 3184 patients by their 
clinical parameters and by their Doppler echo parameters who presented in 
Congestive heart failure. Out of these 95 patients 50 had normal EF> 54%, 19 had 
mildly reduced Ejection fraction 40% -54%, and 26 had EF≤40%. But when 
compared with patients with no signs of congestive heart failure vs. patients with CHF 
with preserved EF had higher creatinine levels and higher prevalence’s of DM (60%-
70% vs 50%) and HTN (75%-96% vs. 46%), disproportionately women, elderly age 
group, and higher systolic blood pressure prolonged DT and a reduced E/A ratio, 
higher LV mass and relative wall thickness and higher BMI , whereas those with CHF 
and EF≤40% had high E/A ratios and short DT. 
Knudsen CW et al 70 did a study in 292 patients presenting with acute dyspnea 
who were having permanent or paroxysmal atrial fibrillation to see the diagnostic 
utilization of BNP in patients either having heart failure or without it. In patients 
without heart failure it was seen that there were increased levels of BNP, but when 
BNP Levels were compared in patients suffering from heart failure either having atrial 
fibrillation or without it levels showed no significant change. Hence concluded that in 
patients without heart failure AF has strong association in form of increased values of 
BNP and hence suggesting that a higher threshold values should be used if a patient 
presented with AF. 
Omar Issa et al 71 studied the size of left atrium and HF related Hospitalization 
in Patients with DD and Preserved EF in 415 patients for 2 years and founded that 
patients with HFPEF had higher BMI, creatinine, beta-blocker use, and Grade 2 
diastolic dysfunction when compared to the hypertensive control population. 
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Echocardiographic analysis demonstrated higher right ventricular systolic 
pressures(42.0±10.4 with p value <0.001), left ventricular mass index(126.2±32.6), 
E/A(1.17±0.62 with p value <0.001), and E/e’(16.4±6.7 with p value <0.001) in 
patients with HFpEF and similar differences were observed in most left atrial (LA) 
parameters including larger LA maximum and minimum volume indices, as well as 
smaller LA-emptying fractions in the heart failure group and found that LA minimum 
volume index(40.2±14.8 with p value < 0.001) have the strongest association with 
heart failure hospitalization after adjustment for creatinine and BMI . 
Delas Fuentes L et al 72 studied the extent to which the criteria for metabolic 
syndrome predict left ventricular (LV) structure and function in 607 patients and 
found that Patients who were having metabolic syndrome were having diastolic 
dysfunction of left ventricle which was independent of Left ventricular mass. And this 
could explain the increased risk of morbidity related to cardiovascular involvement 
and mortality associated with metabolic syndrome. 
NirAyalon et al 73 did a study to see preclinical left ventricular diastolic 
dysfunction amongst metabolic syndrome patients who had no cardiovascular disease. 
In the study 90 patients were enrolled and were compared with control group. All 
patients went echocardiography along with tissue Doppler. The study observed that 
higher left atrial diameter and left ventricular mass with low E/A ratio was seen in 
metabolic syndrome patients.  
Venkatesh Y. Anjan, et al 74 did a study in Northwestern university among 159 
patients under HFPEF programme. They compared clinical characters along with 
echocardiography parameters in HFPEF patients having normal and increased BNP 
levels. They observed that normal BNP values were common in females, young age 
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group. However pulmonary capillary wedge pressure was same in both the groups. 
Higher BNP levels were associated with structural and functional abnormalities of the 
ventricles with decreased diastolic function. They found that 29% of symptomatic 
patients had normal BNP values but had increased pulmonary capillary wedge 
pressure in HFpEF. Hence BNP was an important prognostic marker in patients of 
HFpEF but normal BNP values in symptomatic patients did not rule out chances of 
HFpEF. 
Iwanaga Y et al 75 in 2007 did a study in 295 patients and checked for BNP 
levels along with echocardiography and cardiac catheterization among overweight 
and obese patients. They observed that BMI levels were inversely related to BMI and 
end diastolic wall stress of the patients. 
Mehra MR et al76 examined the association between BNP in heart failure in 
318 patients during 1 year and BNP levels were compared in obese and non obese and 
found that one-fourth were lean , one-third overweight and 35% obese. The results 
showed that Levels of BNP were certainly lower in obese than in non obese patients, 
even though a similar severity of HF and cytokine levels. 
 McCord J et al77 evaluated relationships between BNP, BMI, and CHF in 
1586 subjects in the Breathing Not Properly Multinational Study who had acute 
difficulty in breathing and subjects with more Basal metabolic index were younger on 
observation but were similarly as likely to have heart failure vs non cardiac sources of 
difficulty in breathing and 3-fold difference was seen in mean BNP values at the 
starting and ending of the BMI groups and results showed that BNP levels are inverse 
to BMI. 
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Krauser DG et al 78 did a study in 204 patients having acute CHF to see 
association of amino terminal pro BNP, BNP and BMI levels. The study showed pro 
BNP levels may be falsely negative among overweight patients but bnp levels were 
somewhat more accurate. 
Khan AM et al 79 observed the relation in 7770 subjects between obesity and 
BNP to see role of increased insulin levels along with testosterone levels. They 
showed that obesity had low N-BNP levels along with increase insulin resistance 
among them. On other hand, insulin sensitive patients had minimal reduction in BNP 
levels. 
Tsutamoto T et al 80 studied to find out the relationship between BNP levels, 
renal function and the severity of CHF in 366 subjects and the eGFR was calculated 
by cockroft gault equation and these patients were divided into two groups, one with 
GFR ≥ 60 ml/min and second with GFR ≤ 60 ml/min with all baseline and echo 
parameters were same and found that BNP values were increased in patients with 
GFR values less than 60 ml/min due to decrease clearance from kidneys. 
Matsumoto M et al 81 studied the effects of anemia on levels of plasma brain 
natriuretic peptide in healthy subjects . Total of 1036 patients were enrolled and found 
that in 292 patients, the abnormal BNP levels were present and frequency was higher 
in women compared to men (31% vs 14%) and thus evaluated levels of BNP is 
inversely correlated with hemoglobin and hence concluded that in healthy subjects 
elevated levels of BNP plays a major role in anemia. 
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Hirofumi Ueno et al 82 studied the combined effect of anemia with raised B-
type natriuretic peptide levels which significantly enlightens an increased risk for 
major adverse cardiac events and 185 patients were included in the study with 
predefined values for anemia and assessed the adverse cardiac events and found that 
in anemia, the major cardiac adverse event had high BNP levels and thus, concluded 
the synergistic effect of anemia in addition to high BNP levels significantly enlightens 
an increased risk for MACE.  
Wu AH et al 83 did a study among patients with heart failure and without heart 
failure to see for relation between their haemoglobin and BNP levels. They found that 
significant low haemoglobin levels were seen in patients having heart failure of class 
III-IV NYHA as compared to patients having heart failure of class I-II NYHA. They 
also saw the relation between the severity of anaemia and BNP levels and concluded 
that BNP levels were higher as patients symptoms increased and severity of anaemia 
increased. 
Lund LHet al84 conducted a study ‘Association between use of renin-
angiotensin system antagonists and mortality in patients with heart failure and 
preserved ejection fraction’. 41,791 patients were enrolled from 64 hospitals. Out Of 
these, 16,216 patients with HFPEF (ejection fraction ≥40%; mean age, 75 years; 46% 
women) were either treated (n = 12,543) or not treated (n = 3673) with RAS 
antagonists and found that 1-year survival was 77% for treated patients vs 72% for 
untreated patients and concluded that, in patients with HFPEF the decrease use of 
RAS antagonists was associated with lower all-cause mortality. 
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In the CHARM-Preserved Trial Yusuf S et al 85 studied effects of candesartan 
in patients with chronic heart failure and preserved LV ejection fraction in March, 
1999, and July 2000 in 3,023 patients and patients were prescribed candesartan 
(n=1514, target dose 32 mg OD) or matching placebo (n=1509 with a Median follow-
up of 36.6 months. 333 (22%) patients in the candesartan and 366 (24%) in the 
placebo group experienced the primary outcome). No difference between 
cardiovascular death between groups (170 vs 170), but less patients in the candesartan 
group than in the placebo group were admitted to hospital for CHF once (230 vs 279, 
p=0.017) or multiple times and concluded that Candesartan do have a moderate role in 
preventing admissions for CHF among patients who have heart failure and LVEF 
higher than 40%. 
In the Aldo-DHF randomized controlled trial 86 studied Effectiveness of 
diuretic spironolactone on DF and the exercise capacity in patients with HFPEF 
between March 2007 and April 2012 and included 422 patients with average age of 67 
years. Out of which 213 patients with 52 % being females were given spironolactone 
25 mg on daily basis and in 219 patients were given matching placebo. Patients were 
followed up for a period of 12 months and concluded that Diastolic function in the 
form of E/e' decreased from 12.7 to 12.1 with spironolactone and increased from 12.8 
to 13 with placebo group which was significantly proved by P value <0.001. Peak 
VO2 did not significantly change with spironolactone vs placebo from 16.3 to 16.8 
mL/min/kg and from 16.4 to 16.9 ml/min/kg, Spironolactone causes left ventricular 
remodeling with difference: 6 g/m2 to 1 g/m2; and improved biomarker BNP and 
mildly improved 6-minute walking distance. But Spironolactone causes slight 
hyperkalemia and decreased eGFR but didn’t affected the hospitalization rate. 
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PEP –CHF Study 87 was a randomized double blind trial, comparing placebo 
with perindopril 4mg/day in 850 patients aged > 70year with a diagnosis of heart 
failure treated with a diuretics and an echocardiogram suggesting diastolic 
dysfunction for a mean period of 2.1 years. The primary end point was a composite of 
all-cause mortality and related number of hospitalizations improved symptoms and 
exercise capacity and fewer hospitalizations for heart failure in the first year were 
observed in perindopril group. 
I-PRESERVE Study 88 showed a neutral outcome when angiotensin II receptor 
blocker irbesartan was compared with placebo. 3600 patients, 60 years of age or older 
with a clinical diagnosis of HF and EF > 45% were observed over 48 months the 
primary end points were death and hospitalization for cardiovascular disease.  
Beta blockers effect in heart failure was studied in the SENIORS Trial 89 
which had 2128 patients aged >70 years. It had a diastolic subset and compared 
nebivolol with placebo. The effect of beta –blockade with preserved and impaired EF. 
The effect of renin – angiotensin blockade by irbesartan or ramipril in 
combination with diuretic on quality of life (Qol), regional and global systolic and 
diastolic function was assessed in HFNEF patient in the The Hong Kong Diastolic 
Heart Failure Study 90 in which 150 patients with HFNEF (LVEF >45%) were 
randomized to (1) diuretics alone, (2) diuretics plus irbesartan or (3) diuretics plus 
ramipril. In this typically elderly group of HF patient with normal LVEF, Diuretic 
therapy significant improved symptoms and neither irbesartan nor ramipril marginally 
improved LV function, and lowered NT –proBNP over 1 year. 
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The SWEDIC Study, a double blind multi-Centre study investigates the effects 
of carvedilol as an addition to conventional treatment (e.g. diuretics and/or ACE – 
inhibitors and /or digoxin) on diastolic function in 113 symptomatic patients with HF 
with preserved systolic function and evidence of diastolic dysfunction determined by 
Doppler echocardiography.91 The patients received either carvedilol or matching 
placebo in addition to conventional treatment. At the end of the study there was a 
statistically significant improvement in E: A ratio in patients treated with carvedilol 
(0.72 to 0.83) vs placebo (0.71to 0.76) (p<0.05). 
Wak forest and MCC -135 study is another such on going relevant trail92 
digoxin has been shown to be of benefit in diastolic heart failure, although the result 
of the digitalis investigation group trail suggested that patients with diastolic heart 
failure had fewer symptoms and hospitalization when treated with digoxin 93 however 
in another trial the use of digoxin is also not associated with any benefit in these 
patients.94 
Recent studies found that Non-Cardiac Comorbidities like Diabetes, Obesity is 
common in the general population and the prevalence of obesity has been rising at an 
alarming rate over the past several years. Obesity has been associated with adverse 
cardiac remodeling and dysfunction in both experimental models and in humans, and 
obesity is associated with a high output state. Together, these pathophysiologic 
abnormalities result in the HF syndrome, often with a preserved EF. Thus, the high 
prevalence of obesity in the general population (and the increases in rates of obesity 
over time) contributes to the epidemic of HFpEF. Accordingly, obesity is highly 
prevalent in HFpEF (32–46 %), and high body mass index (BMI) is known to be a 
risk factor for HFpEF. 95-98 In a recent Framingham Heart Study report, higher BMI 
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was shown to be a predictor of HFpEF but not HFrEF.99 In few studies treatment with 
insulin improved post meal glucose values and was associated with improved 
diastolic dysfunction and improved myocardial perfusion. 100 As an another choice to 
medical management if focused on dietary and lifestyle modifications which can be 
the key parts in the prevention and management of heart failure and could be 
extremely beneficial. A low-sodium rich diet known as the DASH diet in a larger 
group of studies has been shown that it significantly reduces the incidence of HF101. 
In the Swedish Mammography Cohort the women who were compliant with the 
DASH diet had a 37 % less chance of development of HF after a mean follow up of 7 
years. The DASH diet is also beneficial in decreasing the incidences of HTN, Stroke, 
and Hyperlipidemia which are commonly seen as comorbid conditions in HFPEF.102-
103 Non-pharmacologic treatment options such as yoga and devices that mimic this 
approach104 hold promise in the treatment of hypertension that often leads to HFPEF 
without the side effects and expense of money. 
 
FIG : 16 – ACC/AHA/HFSA/ESC Guidelines for the treatment of patients with 
stage C Heart Failure And Preserved Left Ventricular Ejection 
Fraction(HFPEF) 
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FIG : 17 Cardiomyocyte structure changes (A-C) and changes of extracellular 
matrix fibrillar collagen (D-F) in HFpEF (outlined in red) versus HFrEF 
(outlined in black) versus findings in referent control group (outlined in green).  
 In HFpEF there is concentric cardiomyocyte remodeling with increased 
diameter. But there is no change in length and there is an increased fibrillar 
collagen thickness, number and content. 
 In HFrEF there is eccentric cardiomyocyte remodeling with the length 
increased. But there is no change in width and fibrillar collagen degradation and 
abnormal structure and turnover. Arrows indicate fibrillar collagen.105 
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FIG : 18 - A, Patients with HFpEF who are considered to be in good 
compensation by physician may have increased LV diastolic pressure (indexed 
here as ePAD)with the development of ADHF necessitating hospital admission, 
B, Both baseline LV diastolic filling pressure and changes in filling pressure are 
good predictors of future ADHF events.106 
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MATERIALS AND METHODS 
1. Material and methods 
A. Study Design : Cross sectional study 
B. Study Period : 18 months 
Sampling Population:  
All the patients attending Cardiology and Medicine OPD And IPD, Sree 
Mookambika Institute of Medical Sciences, Kulasekharam during the decided study 
period.  
a. Inclusion Criteria:  
 Age > 18 and willing to give consent  
 Presence of symptoms and signs of Congestive Heart failure at the time of 
presentation 
 LVEF >50% on detailed Transthoracic echocardiography examination. 
 Presence of LV Diastolic Dysfunction 
b. Exclusion Criteria  
 Patients with LVEF <50% on Transthoracic Echocardiography Examination. 
 Patients with LV dilation. (LVIDd >55mm). 
 Patients with valvular heart disease. 
 Patient not giving consent. 
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METHOD OF COLLECTION OF DATA 
All the patients of suspected clinical diagnosis of heart failure on basis of 
Framingham’s criteria were taken up for the study. 
The Framingham’s criteria are as follows: 
Diagnosis of heart failure requires 2 or major criteria OR 1 major or 2 minor 
criteria: 
Major criteria: 
1. Acute pulmonary edema 
2. Cardiomegaly 
3. Hepatojuglar reflux 
4. Neck veins distension 
5. PND or orthopnea 
6. Pulmonary rales 
7. Third heart sound(S3 gallop rhythm) 
8. Weight loss > 4.5 kg in 5 days in response to treatment. 
Minor criteria 
1. Ankle edema 
2. Dyspnea on exertion 
3. Hepatomegaly 
4. Nocturnal cough 
5. Pleural effusion 
6. Tachychardia  
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a. Sample Size Calculation: 
[n = 4pq/d²; p = 67%   (Jorge AJL et al study) ] 
p = HFPEF with mean BNP value of 153.3± 123.1pg/ml = 67% 
q = 100 – p = 100 – 67 =33 
d = 20% of p = 20% of 67 = 13.4 
n = 4x67x33/ (13.4)2 =8844/179.56  
 = 49.25 = 50 
D. Study Procedure 
All eligible patients enrolled, written and informed consent obtained from 
them. Apart from demographic details, detailed history taken and did physical 
examination and total 5 ml of blood was collected and investigated and suspected 
heart failure patients went through Transthoracic echocardiography and BNP testing 
done to diagnose the heart failure with preserved ejection fraction and classified 
according to diagnostic dysfunction. 
For BNP sampling : 
 Specimen type - Blood plasma 
 Container - Vacutainer, lavender top (EDTA) 
 Collection method - Venipuncture 
 Specimen volume - 2 mL 
 Other instructions - Spin down and freeze plasma immediately; patient age 
and sex required 
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E. Data Collection Methods including Setting and Periodicity:  
All the pertinent data was collected in predesigned data collection form and 
was entered into Microsoft Excel 2013 and analysis was done in SPSS Software 
version 20.0. 
INVESTIGATION TO BE CONDUCTED ON PATIENTS FOR THE STUDY 
All such patients were subsequently submitted to detailed 2D/Doppler 
echocardiography study using EPIQ 7 Philips adult 4D Echo machine using sector 
probe of frequency range between 3-5 Hz. 
Ejection fraction was calculated by Modified Simpsons method. 
Left atrium volume index was calculated by using Simpson’s method for 
volume determination divided by body surface area. 
Mitral inflow velocity examination with pulsed wave Doppler was done in 
apical 4 chamber view by placing sample volume at tip of mitral valve leaflets. 
Doppler Parameters 
Detailed mitral inflow velocity study measuring transmitral E wave and A 
wave velocity, E/A ratio were studied. 
The Diastolic dysfunction was graded as: 
Grade I- Impaired relaxation with normal filling pressure. 
Grade II -moderate dysfunction, pseudonormalised mitral inflow pattern. 
Grade III-severe reversible, reversible restrictive (High Filling Pressure) 
Grade IV-severe irreversible dysfunction irreversible restrictive pattern (High Filling 
Pressure) 
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Simultaneous BNP levels was done by an automated quantitative test by using 
plasma using the ELFA (Enzyme-Linked Fluorescent Assay) technique. 
As per European society of cardiology guidelines on the diagnosis of HFPEF, 
BNP value is divided into 3 groups as  
 <100 pg/ml which is normal value 
100 – 400 pg/ml denotes mild to moderate heart failure  
 >400 pg/ ml suggests Severe heart failure which were compared with various 
parameters associated with HFPEF. 
Other investigations that were done are : 
Complete blood count (Hb, TLC, DLC) 
Renal function test (RFT) 
Liver function test (LFT) 
Lipid Profile 
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RESULTS 
TABLE 1 
Number and percentage of patients based on Gender 
GENDER NUMBER OF PATIENTS PERCENTAGE 
MALE 19 38 
FEMALE 31 62 
 
 
FIG : 19 Number of patients based on Gender 
 In my study total no of patients 50 out of which 31 females ( 62 %) and 19 
male (38%). 
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TABLE 2 
Number and percentage of patients based on BNP Value 
BNP LEVEL (pg/ml) NUMBER OF PATIENTS PERCENTAGE (%) 
<100 6 12 
100-400 9 18 
>400 35 70 
 
 
FIG : 20 –Number of patients based on BNP Value 
Out of 50 patients 35 cases (70 % ) of having BNP > 400 pg/ ml followed by 9 
cases ( 18%) in 100-400 pg/ml range and then 6 people (12%) having < 100 pg/ml. 
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TABLE 3 
Number and percentage of patients based on Diastolic Dysfunction Type 
DIASTOLIC 
DYSFUNCTION TYPE 
NUMBER OF 
PATIENTS PERCENTAGE 
TYPE 1 23 46 
TYPE 2 12 24 
TYPE 3 15 30 
 
 
FIG : 21 –Number of patients based on DD Type 
 Out of 50 patients 23 cases( 46 %) having DD Type 1 followed by 15 cases ( 
30 %) with DD Type 3 and then 12 cases ( 24 %) with DD Type 2. 
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TABLE 4 
AGE DISTRIBUTION OF PATIENTS WITH BNP VALUE IN HFPEF 
 
 
FIG : 22 AGE DISTRIBUTION WITH BNP VALUE 
 As seen from this table, maximum number of cases was in age group of 61-
70(34%) followed by 51- 60 years (28%), >70 years (22%) and 40-50 years(16%). 
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Age / BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand total
40-50YEARS 2 (25%) 2 (25%) 4 (50%) 8 
51-60 YEARS 3 (22%) 2 (14%) 9 (64%) 14 
61-70 YEARS 1 (6%) 3 (18%) 13 (76%) 17 
>70 YEARS  2 (18%) 9 (82%) 11 
Grand total 6 (12%) 9 (18%) 35 (70%) 50 
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In the age group of 40-50 years 2 cases (25%) were having BNP below 100 
pg/ml , 2 (25%) and 4(50%) cases were having 100-400 pg/ml and >400 pg/ml BNP 
respectively.  
In the age group of 51-60 years 3 (22%), 2(14%) and 9(64%) cases were 
having BNP <100 pg/ml, 100-400 pg/ml and >400 pg/ml BNP respectively.  
In the age group of 61-70 years 1(6%) case was having BNP below 100 pg/ml, 
3(18%) and 13(76%) cases were having 100-400 pg/ml and >400 pg/ml BNP 
respectively.  
In the age group of >70 years No case was having BNP below 100 pg/ml but 
2(18%) and 9(82%) cases were having 100-400 pg/ml and >400 pg/ml BNP 
respectively.  
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TABLE 5 
DISTRIBUTION ACCORDING TO SEX WITH BNP VALUE IN HFPEF 
Sex/BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Female 5 (16%) 5 (16%) 21 (68%) 31 
Male 1 (5%) 4 (21%) 14 (74%) 19 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
 
   
FIG : 23 – Correlation between Gender and BNP value 
As seen from this table, majority of the cases were female, with female: male 
ratio being 1.6: 1 with 62 % of the patients being females and 38 % males.  
In females 5 cases (16%), 5 (16%), 21 (68%) were having BNP value <100 
pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In males 1 case (5%), 4 (21%), 14 (74%) were having BNP value <100 pg/ml, 
100-400 pg/ml, >400 pg/ml respectively. 
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TABLE -6 
BODY MASS INDEX (BMI) IN PATIENTS WITH BNP VALUE IN HFPEF 
 
 
BMI = BODY MASS INDEX GRADED ACCORDING TO ASIAN CRITERIA 
FIG : 24 – BMI vs BNP Graph 
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BMI/BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
18.5-22.9 kg/m2 1 (8%) 1 (8%) 11(84%) 13 
23-27.4 kg/m2 4 (14%) 6 (21%) 18 (65%) 28 
27.5-32.4 kg/m2 1 (13%) 2 (25%) 5(62%) 8 
32.5-37.4 kg/m2   1 (100%) 1 
Grand Total 6 9 35 50 
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As seen from the table above majority of the cases were overweight (56%) 
with BMI of 23-27.4 kg/m2, followed by 26 % of the patients were in the normal 
range with BMI of 18.5-22.9 kg/m2. 16% of the patients were obese i.e. BMI 27.5-
32.4 kg/m2 and only 2 % of the patients were in the range of 32.5-37.4 kg/m2 that is 
very obese. 
In Normal BMI group i.e. 18.5-22.9 kg/m2 1 case (8%), 1 (8%), 11 (84%) 
were having BNP value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In overweight BMI group i.e. 23-27.4 kg/m2 4 cases (14%), 6 (21%), 18 (65%) 
were having BNP value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In obese BMI group i.e. 27.5-32.4 kg/m2 1 case (13%), 2 (25%), 5 (62%) were 
having BNP value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In very obese BMI group i.e. 32.5-37.5 kg/m2 only 1 case was having BNP of 
>400 pg/ml. 
The value is statistically significant ( p value – 0.005) 
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TABLE – 7 
ACC TO COMORBITIES IN 50 CASES OF HFPEF 
CVA(CEREBROVASCULAR ACCIDENT), CKD (CHRONIC KIDNEY 
DISEASE), OSA (OBSTRUCTIVE SLEEP APNOEA) 
As seen from this table, it is clear that majority of the patients were 
hypertensive (68%) and diabetic ( 62%) with 26 % hyperlipidaemic and and 26 % 
anaemic. 6 % of the patients were having AF. Hypothyroidism was seen in 6 % of the 
cases, CVA in 6 %, chronic kidney disease (CKD) in 4 % and obstructive sleep 
apnoea (OSA) in 2 %. Thus as seen from this table majority of the patients of heart 
failure with preserved ejection fraction had associated co-morbid condition. 
 
 
 NUMBER OF CASES (n=50) PERCENTAGE (%) 
ANAEMIA 13/50 26 
HYPERTENSION 34/50 68 
CKD 2/50 4 
DIABETES 
MELLITUS 31/50 62 
HYPOTHYROIDISM 3/50 6 
ATRIAL 
FIBRILLATION 3/50 6 
CVA 3/50 6 
HYPERLIPIDAEMIA 13/50 26 
OSA 1/50 2 
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TABLE -8 
RELEVANCE OF BNP IN HYPERTENSIVE AND NON HYPERTENSIVE 
PATIENTS IN HFPEF 
BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Non Hypertensive 4 (25%) 5 (31%) 7 (44%) 16 
Hypertensive 2 (6%) 4 (12%) 28 (82%) 34 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
 
FIG : 25 - Impact of Hypertension on BNP value 
As seen from this table, it is clear that majority of the patients were 
hypertensive (68%) and non hypertensive (32 %). 
In hypertensive patients 2 cases (6%), 4 (12%), 28 (82%) were having BNP 
value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In Non Hypertensive patients 4 cases (25%), 5 (31%), 7 (44%)were having 
BNP value <100 pg/ml, >400 pg/ml respectively. 
The value is statistically significant ( p value – 0.019) 
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Table- 9 
RELEVANCE OF BNP IN DIABETIC AND NON DIABETIC PATIENTS IN 
HFPEF 
BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Non Diabetic 4 (21%) 8 (42%) 7 (37%) 19 
Diabetic 2 (6%) 1 (3%) 28 (91%) 31 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
 
FIG : 26 – Impact of Diabetes on BNP value 
As seen from this table, majority of the patients were Diabetic (62%) and Non 
Diabetic (38 %). 
In Diabetic patients 2 cases (6%), 1 (3%), 28 ( 91%) were having BNP value 
<100 pg/ml, 100-400 pg/ml ,>400 pg/ml respectively. 
In Non Diabetic patients 4 cases (21%), 8 (42%), 7 (37%) were having BNP 
value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively 
The value is statistically significant ( p value – 0.0001) 
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TABLE - 10 
RELEVANCE OF BNP IN DYSLIPIDEMIC AND NON DYSLIPIDEMIC 
PATIENTS IN HFPEF 
BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Normal 6 (16%) 9 (24%) 22 (60%) 37 
Dyslipidemic   13 (100%) 13 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
 
FIG : 27 – Correleation between dyslipidemia and BNP value 
As seen from this table, majority of the patients were Non dyslipidemic (74%) 
and Dyslipdemic (26%). 
In Non Dyslipdemic patients 6 cases (16%), 9 (24%) , 22 (60%) were having 
BNP value <100 pg/ml,100-400 pg/ml, >400 pg/ml respectively. 
In Dyslipdemic patients 13 cases were having BNP value >400 pg/ml . 
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TABLE 11 
RELEVANCE OF BNP WITH HAEMOGLOBIN LEVEL IN PATIENTS 
WITH HFPEF IN FEMALES 
 
FIG : 28 – BNP value with Hb level in females 
 Majority of the patients in study were having normal haemoglobin level that 
is 23 cases (74%) followed by Mild anaemic 6 cases ( 19%) and then 2 Moderate 
anaemic cases (6 %). 
In normal people 4 cases ( 17%) , 3 ( 13%) , 16 ( 70 %) were having BNP 
value <100 pg/ml,100-400 pg/ml, >400 pg/ml respectively. 
In mild anaemic 1 case ( 17% ) , 2 cases ( 33 %) , 3 ( 50 % ) were having BNP 
value <100 pg/ml,100-400 pg/ml, >400 pg/ml respectively. 
In moderate anaemic 2 cases were there which were having BNP > 400 pg/ml. 
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Hb (gm/dl) BNP >100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Normal (>12) 4 (17%) 3 (13%) 16 (70%) 23 
Mild ( 10-11.9) 1 (17%) 2 (33%) 3 (50%) 6 
Moderate (7- 9.9) 2 (100%) 2 
Grand Total 5 (16%) 5 (16%) 21 (68%) 31 
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TABLE - 12 
RELEVANCE OF BNP WITH HAEMOGLOBIN LEVEL IN PATIENTS 
WITH HFPEF IN MALES 
 
 
FIG : 29 - BNP value with Hb level in females 
Majority of the patients in study were having normal haemoglobin level that is 
14 cases (74%) followed by Mild anaemic 5 cases ( 26% ). 
In normal people 1 cases ( 7%) , 4 ( 29%) , 9( 64 %) were having BNP value 
<100 pg/ml,100-400 pg/ml, >400 pg/ml respectively. 
In mild anaemic 5 cases were there which were having BNP > 400 pg/ml. 
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Haemoglobin/ BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total
Normal ( > 13) 1 (7%) 4 (29%) 9 (64%) 14 
Mild ( 11- 12.9 )  5 (100%) 5 
Grand Total 1 (5%) 4 (21%) 14 (74%) 19 
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TABLE- 13 
RELEVANCE OF BNP WITH NYHA GRADING IN PATIENTS WITH 
HFPEF 
 
FIG : 30 – Correlation between NYHA grade and BNP value 
As seen this table majority of the patients of heart failure with preserved 
ejection had NYHA Class III (58 %) followed by class IV (42 %), which suggests that 
the patients were in failure at the time of presentation. 
Most of the patients were in NYHA grade III i.e patients came with dyspnea 
on exertion associated with orthopnea/PND which were 6 cases (21%), 6 (21%) , 17 
(58%) having BNP value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
3 cases (14%) , 18 (86%) were having BNP value <100 pg/ml, >400 pg/ml 
respectively in NYHA Grade IV patients. 
The value is statistically significant ( p value – 0.049) 
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BNP <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total 
NYHA GRADE 3 6 (21%) 6 (21%) 17 (58%) 29 
NYHA GRADE 4 3 (14%) 18 (86%) 21 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
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TABLE-14 
2-D ECHO PARAMETERS (M-MODE VARIABLES) 0F 50 CASES 
M- MODE VARIABLES BASELINE MEAN ± SD 
LA 39.86 ± 5.97 mm (21-37mm) 
LVID d 42.72 ± 7.30 mm (25-52mm) 
LVID s 27.54 ± 5.2 mm (23-39 mm) 
EF 58.78 ± 2.78 % (55-85%) 
LA- LEFT ATRIUM, LVID D- LEFT VENTRICULAR INTERNAL 
DIAMETER IN DIASTOLE, LVID S- LEFT VENTRICULAR INTERNAL 
DIAMETER END SYSTOLE, EF- EJECTION FRACTION 
As seen from the above table mean left atrium size was 39.86 ± 5.97 mm, 
mean left ventricular internal diameter in diastole was 42.72 ± 7.30 mm, mean left 
ventricular internal diameter in systole was 27.54 ± 5.2 mm with a mean normal 
ejection fraction of 58.78 ± 1.57 %. From this analysis it suggested that mean LA size 
was prominent in majority of the patients, LVIDd, LVIDs and ejection fraction was 
normal in all the cases. 
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TABLE -15 
RELEVANCE OF BNP WITH LEFT ATRIAL DIAMETER IN PATIENTS 
WITH HFPEF 
LA Diameter <100 pg/ml 100-400 pg/ml >400 pg/ml Grand Total 
30-40 mm 6 (26%) 7 (30%) 10 (44%) 23 
>40 mm 2 (7%) 25 (93%) 27 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
 
FIG : 31 – Impact of Left Atrial Diameter on BNP value 
From this analysis it is suggested that mean LA diameter was prominent in 
majority of the patients i.e. 54% as >40 mm of Left atrium size followed by 46% with 
normal range which is 30-40 mm. 
In LA enlarged patients 2 cases (7%), 25(93%) were having BNP value 100-
400 pg/ml, >400 pg/ml respectively. 
In normal LA patients 6 case (26%), 7 (30%), 10 (44%) were having BNP 
value <100 pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
The value is statistically significant ( p value – 0.001) 
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TABLE - 16 
DOPPLER ECHOCARDIOGRAPHIC VARIABLES OF 50 CASES 
DOPPLER VARIABLES MEAN ± SD 
E Velocity 1.02 ± 0.23 m/s 
A Velocity 0.85 ± 0.27 m/s 
E/A Ratio 1.29 ± 0.54 
E/e’ Ratio 15.49 ± 6.1 
 E= EARLY FILLING, A= ATRIAL FILLING, e’=EARLY DIASTOLIC 
VELOCITY 
As seen from the above table Doppler echocardiographic variables for 
diastolic function mean early filling velocity ( E) value was 1.02 ± 0.23 m/s, mean 
atrial filling (A) velocity value was 0.85 ± 0.27 m/s, mean E/A ratio was 1.29 ± 0.54, 
with a mean ( E/e’) ratio was 15.49 ± 6.1 which suggested that left ventricular end 
diastolic pressure was raised. 
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TABLE- 17 
RELEVANCE OF BNP WITH E/A RATIO IN PATIENTS WITH HFPEF 
 
 
FIG : 32 – Correlation of E/A ratio with BNP value 
Most of the patients were having E/A ratio >1 that is 62% followed by 38% 
which was E/A <1. 
3 cases (10%) , 4 (13%) , 24 (77%) were having BNP value <100 pg/ml, 100-
400 pg/ml, >400 pg/ml respectively with E/A ratio >1. 
3 cases (16%) , 5 (26%) , 11 (58%) were having BNP value <100 pg/ml, 100-
400 pg/ml, >400 pg/ml respectively with E/A ratio <1. 
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<1 3 (16%) 5 (26%) 11(58%) 19 
>1 3 (10%) 4 (13%) 24 (77%) 31 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
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TABLE - 18 
RELEVANCE OF BNP WITH DIASTOLIC DYSFUNCTION TYPE IN 
PATIENTS WITH HFPEF 
 
FIG : 33- Impact of DD type on BNP value. 
Most of the patients were having Diastolic Dysfuction type 1, that is 23 cases 
(46%) followed by DD type 3 were 15 (30%) and then DD type 2 were 12(24%) . 
In DD type 1- 5 cases(22%), 7(30%), 11(48%)were having BNP value <100 
pg/ml, 100-400 pg/ml, >400 pg/ml respectively. 
In DD type 2- 1 case (8%), 1(8%), 10(84%)were having BNP value <100 
pg/ml, 100-400 pg/ml, >400 pg/ml respectively 
In DD type 3- 1 case (7% ), 14 (93% ) were having BNP value 100-400 pg/ml, 
>400 pg/ml respectively. 
The value is statistically significant ( p value – 0.033) 
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Total 
DD Type 1 5 (22%) 7 (30%) 11 (48%) 23 
DD Type 2 1 (8%) 1 (8%) 10 (84%) 12 
DD Type 3 1(7%) 14 (93%) 15 
Grand Total 6 (12%) 9 (18%) 35 (70%) 50 
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DISCUSSION 
Heart failure with preserved ejection fraction (HFPEF) is associated with 
substantial morbidity and mortality. Existing data suggests that the patients with 
HFPEF are increasing over time and hospitalization rates, death rates are approaching 
the patients with heart failure with reduced ejection fraction. 
To know correct identification of patients with HFPEF and to differentiate 
between cardiac patients and dyspnoea due to non-cardiac causes studies should be 
done to know the proper diagnostic guidelines for HFPEF. In our study, relevance of 
BNP in heart failure with LVEF ≥ 50% and absence of left ventricular dilation 
(LVIDd ≤ 55 mm) on echo examination along with Presence of symptoms and signs 
of Congestive Heart failure at the time of presentation and evidence of diastolic 
dysfunction on Doppler examination were used to diagnose heart failure with 
preserved ejection fraction. 
The present study is an observational study of 50 patients of heart failure with 
preserved ejection fraction in whom baseline characteristics of the patients in terms of 
age & sex distribution, vital parameters, laboratory parameters, comorbities, M- mode 
echocardiography , NYHA class, Diastolic dysfunction type at the time of 
presentation, and correlation of various parameters and echocardiographic variables 
with BNP were studied. 
AGE AND BNP IN HFPEF 
The mean age of our patients was 63.06 years and majority were in group of 
61-70 years of age that is 34 %. In Devereux et al69 showing mean age of 64 years, 
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MacCarthy et al showing mean age of 63 years, This observation can be attributable 
as HFPEF is more common in elderly age group. 
In our study, we found out that BNP values are closely associated with age. As 
the age increases BNP value tends to increase. In Kayzer JM et al analysis of variance 
demonstrated that BNP data were significantly dependent on age (p<0.001)107 
Mottram PM et al studied that in patients with HF with normal ejection 
fraction, BNP is related to Age and blood pressure.108 
GENDER AND BNP IN HFPEF 
Along with age in present study HFPEF was more common in female with 
female to male ratio of 1.6:1. Present study observed that 62% patients of HFPEF 
were females which suggesting that diastolic dysfunction is more commonly seen in 
females which is consistent to other studies i.e. Devereux et al 69 showing 84% of 
females, Lee et al 66 showing 65% of females and Bursi et al67 showing 57 % of 
females. 
As seen from our study, there were 62 % females with 38 % males and 
showed females having more BNP value as compared to males suggesting that gender 
having direct correlation with BNP value. Roongsritong C et al study showed BNP 
was significant and he found out that BNP values are higher in women with diastolic 
dysfunction than males(p=0.002).109 Kayzer et al found out that that BNP data were 
significantly dependent on gender (p=0.002).107 
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BMI AND BNP 
In present study majority of our patients were overweight (56%) with BMI of 
23-27.4 kg/m2 and had elevated BNP leves as in other studies like in Lee et al66 study 
mean BMI was 27kg/m2, , in Devereux et al69 was 33.1 kg/m2 and Bursi et al67 mean 
BMI was 30kg/m2. This difference in mean can be attributed to the ethnicity and 
baseline difference in height and weight of the patients. In present study we observed 
that only 12% of the patient with high BMI showed BNP in normal range.  
VARIOUS COMORBID CONDITIONS IN HFPEF 
The present study showed that 68 % of patients were hypertensive, 62% were 
diabetic, 26% were anaemic, 26% were having hyperlidaemia, 6 % had AF, 6% had 
hypothyroidism. This observation was comparable to Lee et al 66 which had 59% 
patients as hypertensive, 22 % as diabetic, 29 % having atrial fibrillation and 59 % 
showed hyperlipidaemia. Bursi et al 67 study showed that 86 % patients as 
hypertensive, 36 % as diabetic and 31 % having atrial fibrillation. 
HYPERTENSION AND BNP 
It has been seen that HFPEF is more commonly seen in patients having 
hypertension. In present study it was found that 68 % were hypertensive and a mean 
systolic BP was 167.8 mm Hg & mean diastolic was 103.8 mm Hg and had higher 
BNP values as compared to non hypertensive patients. Our study is statistical 
significant ( p – 0.019) 
 Lee et al66, Devereux et al69 , it was found that baseline mean blood pressure 
was high in 59 %,and 76 % respectively. 
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Mottram PM et al studied that in hypertensive patients with symptoms 
suggestive of HF with normal ejection fraction, BNP is related to Hypertension with 
atrial and ventricular systolic parameters.108 
This observation is because of the underlying pathophysiology of HFPEF due 
to hypertension causing the pressure overload leading to left ventricular hypertrophy 
and fibrosis and leading to diastolic dysfunction. It has been seen that isolated systolic 
hypertension in patients with heart failure causes concentric hypertrophy in females 
and eccentric hypertrophy in males and this could be the one reason that could 
contribute to increased risk of diastolic dysfunction more in women than males. 
Furthermore, hypertension causes increased left atrial pressure and resulting in 
pulmonary venous hypertension and increased signs and symptoms of heart failure. 
Physical examination can also reveal signs of hypertension by loud A2, laterally 
displaced cardiac impulse.  
DM AND BNP 
In our study 31 patients out of 50 were diabetic (62 % ) and showed directly 
relation with BNP values as there is higher values in diabetic patients. Our study is 
statistical significant (0.001). 
Dal k et al study showed High BNP levels were directly correlated with 
HbA1C and FBS values.110 This showed that diabetic patients are more prone for 
getting diastolic dysfunction as compared to normal individual and directly linked 
with BNP value.  
 
Discussion 
 
	 	68	
 
ANAEMIA AND BNP 
In our study, Most of the patients were non anaemic but patients with low Hb 
levels had high BNP value. As in females 8 patients were anaemic out of which 5 
patients had BNP value more than 400 pg/ml and in males 5 cases were anemic all 
showed high BNP value with more than 400 pg/ml. 
Hirofumi Ueno et al82 studied the correlation between anaemia, BNP and the 
outcome in 185 patients with heart failure and found that synergistic effect of 
anaemia combined with high BNP levels significantly predicts an enhanced risk for 
major adverse cardiac events. In other study by Wu AH et al83 which studied the 
relationship of anaemia and BNP in patients with and without heart failure and it was 
found that incidence of anaemia was higher in patients with heart failure (48% v/s 
32%) with a higher mean BNP value (439 pg/ml v/s 35pg/ml). 
ECHOCARDIOGRAPHIC VARIABLES IN HFPEF 
M mode echocardiography variables of our 50 patients were studied. The 
various parameters included LA size, LVIDd, LVIDs and LVEF. Mean LA size was 
enlarged in all the patients with mean size of 39.86 mm. In a study done by Omar Issa 
et al71 studied the correlation of LA size in HFPEF and founded that mean LA size 
was enlarged in all patients with HFPEF with a mean of 40.2 mm. In another study by 
Angela B. S. Santos et al111 studied the LA function by strain analysis using speckle 
tracking as a direct measure of intrinsic LA myocardial deformation in 357 patients in 
HFPEF and found that mean LA size was enlarged. This could be due to the alteration 
of LV diastolic function leading to reduced LV recoil and suction during diastole. As 
a result, these patients are more dependent on atrial pump function in late diastole to 
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maintain normal ventricular filling i.e. more afterload and more chamber tension and 
with progressive elevation of LV filling pressure there will be remodelling and this 
compensatory mechanism will gradually impair resulting in elevated left atrial 
pressure. Patients with enlarged LA size hospitalized more as compared to normal 
size. Recent studies are showing that patients with HFPEF had increased left atrial 
contribution to LV filling as a compensatory response to impaired early LV filling 
during submaximal exercise and these patients have more exercise related symptoms 
and as the disease progresses left atrial function failed to increase, resulting in 
insufficient compensation during late diastolic filling and heart failure progresses and 
symptoms suddenly aggravates. 
We also studied Doppler echo parameters namely E velocity, A velocity, E/A 
ratio, e’ velocity and E/e’ ratio.Zile et al found E/A ratio of 1.05 ± 0.74, E/e’ at lateral 
annulus of 10 ± 4.5 at baseline in 745 patients. The results of these studies are 
consistent with our findings. 
NYHA AND BNP 
In our study majority of the patients of heart failure with preserved ejection 
fraction had NYHA Class III (58 %) followed by class IV (42 %), which suggests that 
patients were in failure at the time of presentation. Most of the patients in grade III 
and Ⅳ of NYHA class having higher BNP suggesting its direct correlation with 
NYHA class as Higher NYHA Class showed higher BNP Values. The value is 
statistically significant ( p value – 0.049) 
Wu ah et al 83 showed in patients with heart failure with a higher mean BNP 
value had NYHA class III and IV. 
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DIASTOLIC DYSFUNCTION AND BNP 
Regarding diastolic dysfunction we had 23 patients with baseline diastolic 
dysfunction grade I. 12 patients with diastolic dysfunction with grade II. 15 patients 
was in diastolic dysfunction with grade III. 
Edelmann et79 al also graded diastolic dysfunction at baseline. Majority of the 
patients had diastolic dysfunction grade I which was consistent with our findings and 
also he checked diastolic dysfunction at 12 months after giving treatment with 
spironolactone and 98 % of the patients continued to have same type of grades even 
though after controlling hypertension.  
In our study, higher the dystolic dysfunction, level of BNP is also higher and 
Diastolic Dysfunction Type 3 showed elevated BNP values compared to Type 1 and 2 
which is statistically significant( p- 0.0333) as Scardovi AB et al study showed B- 
type natriuretic peptide was higher in patients with severe diastolic dysfunction than 
in those without(459±462pg/mL vs 142±166pg/mL,) 112 .This study was significant (p 
<0.001).  
LEFT ATRIAL DIAMETER IN HFPEF AND BNP 
We also studied the correlation of LA diameter with BNP and found that more 
the LA diameter more is the BNP values which was supported by Venkatesh Y. Anjan 
study.74 They compared the clinical characteristics including LA size in 139 patients 
with BNP < 100 pg/ml and with BNP > 100 pg/ml and found that patients with large 
LA size had raised BNP values and patient with BNP< 100 pg/ml had normal LA 
size. It is concluded that BNP values correlates with the LA size. In our study which 
showed mean LA size was prominent in majority of the patients i.e. 54% as >40 mm 
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of Left atrium size followed by 46% with normal range which is 30-40 mm. In LA 
enlarged patients 25 cases out of 27 were having BNP value >400 pg/ml. Our study is 
statistically significant ( p value- 0.001). 
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SUMMARY 
Heart failure with preserved ejection fraction (HFPEF) contributes about 40-
50 % of total cases of heart failure. The present study of 50 cases of HFPEF was 
aimed at highlighting the relevance of Brain natriuretic peptide in various parameters 
of HFPEF along with importance of Doppler echocardiographic indices of diastolic 
dysfunction and associated comorbities which are commonly associated with this type 
of heart failure. 
 All the 50 patients of HFPEF were taken on the basis of heart failure symptoms 
according to Framingham’s criteria, Doppler echo indices of diastolic 
dysfunction EF of ≥ 50 %, absence of Left ventricular dilation. 
 In the present study, out of 50 cases of HFPEF, maximum number of the cases 
was in the age group of 61-70 years of age and majority of them were females . 
This study shows that elevated BNP is seen more commonly in elderly women. 
 Majority of the patients were hypertensive and diabetic in our study. 
 Out of the 50 cases majority were overweight/obese as per their BMI indices 
.This study implying obesity constitutes an important risk factor in development 
of HFPEF and directly associated with BNP . 
 Most of the cases had some associated comorbities like anaemia, 
dyslipidaemias, Hypothyroidism, Atrial fibrillation, OSA and demonstrates 
correlation with HFPEF and BNP and should be treated simultaneously to 
decease the overall mortality . 
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 Most of the patients in grade III and Ⅳ of NYHA class having higher BNP 
suggesting its direct correlation with NYHA class as Higher NYHA Class 
showed higher BNP Values. 
 As the DD severity aggravated, the percentage of higher BNP also increased 
which showed BNP values directly dependent on Diastolic Dysfunction Type. 
 On Doppler echocardiographic variables mean LA Diameter was increased in 
most of the patients. There is significant correlation between LA size and BNP 
levels implying that BNP levels increases as the LA size increases which can be 
an indirect measure for diastolic dysfunction and can guide regarding the 
monitoring of the treatment . 
 The result obtained from this study is comparable with international studies 
showing the association of BNP with various parameters and HEPEF. 
Conclusion 
 
	 	74	
 
CONCLUSION 
To conclude that HFPEF is a major and growing health problem and has 
become a huge economic burden and representing half of all patients with heart 
failure. Despite improvement in understanding of the disease, the challenge lies in 
diagnosis of these cases to start early management. 
Advancement in the diagnostic algorithm, imaging and blood test BNP will 
allow early diagnosis so that treatment may be implemented early in the disease 
progression. All these patients can be benefited from blood pressure control, heart 
failure education (DASH diet, Exercising, Yoga), Diabetic management and 
diagnosing and treating the other comorbities like anemia, obesity which can be the 
leading causes of HFPEF. 
 Serum BNP can be used as a marker for the correlation in which diagnosis is 
not clear .However the awareness of this condition and associated factors is necessary 
to manage this condition. In this study it was seen that hypertension, diabetes mellitus, 
Left atrial diameter were commonly associated with HFPEF and BNP. Other 
comorbidities like AF, obesity, dyslipidemia, atrial fibrillation were also seen..  
So Serum BNP levels helps in stratifying patients for prognosticating but 
further studies are required to identify patients who may get benefit from close 
surveillance and tighter control of their risk factors. 
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LIMITATIONS OF THE STUDY 
 The study was conducted at a medical college hospital which is a tertiary care centre 
and the demographic data of the cases studied may not be a representative sample of the 
whole population or a particular region. 
 The short duration of study and the small number of cases in comparison to the disease 
burden are the limitations of this study  
Recommendations 
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RECOMMENDATIONS OF THE STUDY 
 We recommend that further studies can be done on a larger scale in a population based 
setting 
 It is not enough to only study the prevalence but we need to evaluate the treatment 
modalities which was not done in this study. 
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SREE MOOKAMBIKA INSTITUTE OF MEDICAL SCIENCES 
Padanilam, Kulasekharam, K.K. Dist, Tamilnadu – 6291 61 
DEPARTMENT OF GENERAL MEDICINE 
 
RELEVANCE OF SERUM BNP LEVEL IN THE STUDY OF HEART FAILURE 
WITH PRESERVED EJECTION FRACTION AT TERTIARY CARE HOSPITAL 
 
 
CASE RECORD FORM 
 
OPD/IPD No. :       Date: 
Age:        Gender:  
  
Marital Status:      Occupation:   
Address:        Chief Complaints: 
Past History 
 DM - Yes  No  
 HTN - Yes  No  
 TB  - Yes  No  
 MI - Yes  No     
 Stroke - Yes  No  
 Renal Dysfunction - Yes  No  
 Liver Disease  - Yes  No  
 COPD - Yes  No  
Family History: 
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General Examination 
1) Pallor Present/ Absent 
2) Pedal Edema Present/ Absent 
3) Icterus Present/ Absent 
4) Cyanosis                                  Present/ Absent 
5) Clubbing                                  Present/ Absent 
6) Lymphadenopathy                   Present/ Absent 
7) Pedal edema                            Present/ Absent 
8) JVP                                          Present/ Absent 
Height :    ……….. cm   Wt : ……….kg   BMI 
…….kg/m 2  
Pulse:  ………..bpm   BP: …………...mmhg  
Framingham Criteria for Congestive Heart Failure 
Diagnosis of CHF requires the simultaneous presence of at least 2 major criteria or 1 
major criterion in conjunction with 2 minor criteria. 
Major criteria: 
 Paroxysmal nocturnal dyspnea    Yes  No  
 Neck vein distention     Yes  No  
 Rales       Yes  No  
 Radiographic cardiomegaly    Yes  No  
 Acute pulmonary edema    Yes  No  
 S3 gallop      Yes  No  
 Hepatojugular reflux      Yes  No  
 Weight loss  >4.5 kg in 5 days in response to treatment Yes  No  
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Minor criteria: 
 Bilateral ankle edema     Yes  No  
 Nocturnal cough     Yes  No  
 Dyspnea on ordinary exertion    Yes  No  
 Hepatomegaly      Yes  No  
 Pleural effusion     Yes  No  
 Tachycardia (heart rate>120 beats/min.)  Yes  No  
BASE LINE INVESTIGATION  
 Hb :  
 TLC : 
 DLC :  
 RBS : 
 RFT : 
 LIPID PROFILE: 
 LFT: 
 BNP : 
 ECG: 
Urine  
i) R: 
ii) M: 
Echo Parameters 
 LA (mm)   
 LVID (ed)                                
 IVS (ed)   
 EF(%)                                  
 E/A  ratio 
 MVDT 
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 LV PW (ed) 
 RWMA 
Pericardial Effusion/Disease: 
Diastolic dysfunction grade: ………………………………… 
Grade I        (Impaired relaxation with normal filling pressure.) 
Grade II      ( moderate dysfunction, pseudonormalised mitral inflow pattern) 
Grade III   severe reversible, reversible restrictive (High Filling Pressure) 
Grade IV    (severe irreversible dysfunction irreversible restrictive pattern (High Filling 
Pressure) 
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INFORMED CONSENT DOCUMENT (ICD) 
PATIENT/PARTICIPANT INFORMATION SHEET 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
1. Title of the Study:-  Relevance of Serum BNP Level in the study of Heart 
Failure with Preserved Ejection Fraction at Tertiary Care 
Hospital 
2. Name of the investigator     :  Dr. Ankush Gupta 
  Postgraduate – MD General Medicine 
  Sree Mookambika Institute of Medical 
  Sciences 
 Kulasekharam 
 Mobile: 8529588758 
 Email : dr.guptankush@gmail.com 
Name of the Guide : Dr. J. Kaniraj Peter 
   Professor and HOD 
   Department of General Medicine 
Sree Mookambika Institute of Medical 
Sciences (SMIMS) 
Kulasekharam 
                                                                         Mobile: 9443145209 
e-mail:dr.kaniraj@gmail.com 
 Name of co-guide :  Dr  Ajay Kumar 
 Chief Cardiologist and Assistant Professor 
 Department of Cardiology 
 Sree Mookambika Institute of Medical 
 Sciences 
 Kulasekharam 
                                                                      Mobile : 9446565626 
                                                                      Email : drajaykumarr@gmail.com 
3. Purpose of this project/study:  Diastolic dysfunction is difficult to differentiate 
from systolic dysfunction on the basis if history, physical examination, and 
electrocardiographic and chest radiographic findings. Therefore objective testing with 
Doppler echocardiography and possibly measurements of serum levels of Brain-Type 
Appendices 
 
	 	
 
natriuretic peptide (BNP) is often required. BNP and N Terminal-Pro BNP levels are 
found to be related to the severity of left diastolic dysfunction. 
The treatment of diastolic heart failure is also less well defined then the 
treatment of systolic heart failure and remains a challenge. Hence the need for study. 
It is planned to study all such cases of heart failure with normal ejection fraction 
(HFNEF) in detail by ECHO and raised brain type natriuretic peptide (BNP) levels. 
This study may help us understand the characteristic of this disorder. 
4. Procedure/ methods of the study:  
All eligible patients will be enrolled, written and informed consent will be obtained 
from them. Apart from demographic details, detailed history will be taken and 
physical examination, routine and blood investigation will be done and suspected 
heart failure patients will go through Transthoracic echocardiography and BNP testing 
to diagnose the heart failure with preserved ejection fraction and will classified acc to 
diagnostic dysfunction. 
5. Expected duration of the subject participation:-  Single visit 
6. The benefits to be expected from the research to the participant:   To decrease 
the  Mortality and morbidity rate among heart failure patients. 
7. Any risk expected from the study to the participant:-  Nil 
8. Maintenance of confidentiality of records:- All data collected for the study will 
be kept confidentially. No personal details will be revealed. 
9. Provision of free treatment for research related injury:- Yes 
10. Compensation for participating in the study:- No 
11. Compensation to the participants for forseable risks and unforeseeable risks 
related to research study leading to disability or death:- No 
12. Freedom to withdraw from the study at any time during the study period 
without the loss of benefits that the participant would otherwise be entitled:- 
Yes 
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13. Possible current and future uses of the biological material and of the data to 
be generated from the research and if the material is likely to be used for 
secondary purposes, or would be shared with others, this should be 
mentioned:- N/A 
14. Whom do I contact for further information:  
 
 
 
 
 
 
 
 
Place: Kulasekharam                        
Date:  
        Signature of Participant 
 
 
 
 
 
 
 
 
 
 
 
 
For any study related queries, you are free to contact 
Dr. Ankush Gupta 
Post Graduate – MD General Medicine 
Department of General Medicine 
Sree Mookambika Institute of Medical Sciences, 
Kulasekharam 
Mobile number: 08529588758 
e-mail: dr.guptankush@gmail.com 
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CONSENT FORM 
TITLE OF THE PROJECT:-  Relevance of Serum BNP Level in the study of Heart 
Failure with Preserved Ejection Fraction at Tertiary Care Hospital 
PARTICIPANTS NAME: 
ADDRESS: 
 The details of the study have been provided to me in writing and explained to 
me in my own language. I confirm that I understood the above study and had the 
opportunity to ask questions, I understand that my participation in this study is 
voluntary and that I am free to withdraw at any time. Withdraw at any time, without 
giving any reason, without the medical care that will be normally be provided by the 
hospital being affected. I agree not to restrict the use of any data or results that arise 
from this study provided such a use is only for scientific purpose. I have been given 
an information sheet giving details of this study. I fully consent to participate in the 
above study. 
(I also consent/ do not consent to use my stored biological samples for future 
scientific purposes: Yes/No – if Applicable) 
 
Signature of the Participant:      Date:    
Signature of Witness:      Date:    
Name and Address of Witness: 
Signature of the Investigator:     Date:    
 
 
SYST. DIAS.
1 75 M 165 74 HTN/COPD/AF 27.2 160 100 100 16 7700 186 36 1.1 230 0.8 2012 IV 41 32 34 28 60 0.94 1.25 0.75 12 1
2 67 M 170 71 HTN/AF 24.5 200 100 116 13 10500 191 46 1 210 0.4 670 III 36 29 27 30 52 1.35 0.54 1.4 18 1
3 87 M 180 72 CVA/HTN/AF 22.2 150 100 78 14 8500 109 22 0.8 149 0.5 18000 III 45 25 32 25 62 1.35 0.58 2.3 30 2
4 93 F 158 60 HTN 24 150 90 102 13 9800 224 32 0.9 148 0.6 2239 IV 42 28 50 22 62 1.06 0.5 2.1 22 1
5 60 F 160 70 HTN 27.3 150 100 82 15 12300 100 22 0.8 229 0.6 2090 III 42 30 45 30 58 1.02 0.6 1.7 18 1
6 40 F 162 70 x 26.7 110 70 120 13 7600 128 26 0.8 180 0.4 98 III 38 33 52 23 64 1.1 0.88 1.3 10 1
7 50 M 170 82 HTN/DM/CVA 28.3 180 110 100 11 8200 161 29 0.4 143 0.9 498 III 53 31 52 29 60 1.07 0.7 1.5 9 1
8 56 F 160 70 x 27.3 120 70 100 14 20000 100 25 1.1 180 0.2 367 III 34 26 38 26 52 0.98 0.68 1.02 13 1
9 70 M 166 78 HTN/COPD 28.3 210 170 86 13 6000 160 29 1 193 0.7 481 III 23 23 31 20 55 0.96 0.68 1.4 13 1
10 62 F 162 65 HTN/DM/CKD 24.7 150 90 88 12 20000 100 98 3.7 160 0.3 4047 IV 44 22 45 23 60 1.21 0.84 1.4 25 3
11 65 F 165 60 x 22 120 84 98 12 5600 112 26 0.3 150 0.2 220 III 39 26 43 22 60 0.63 0.84 0.75 12 1
12 55 F 180 80 HTN/AF 24.7 140 90 90 12 11400 120 36 1.2 168 6.9 8998 IV 41 26 40 23 60 1.2 0.9 1.33 19 2
13 80 F 158 56 HTN/DM 22.4 170 100 108 14 14500 102 30 1.2 188 0.8 2849 IV 41 28 30 26 64 1.06 0.5 2.1 20 1
14 63 M 154 58 DM 24.5 100 60 90 15 8600 100 23 0.7 140 2.9 1094 IV 51 27 50 37 62 1.3 0.62 2 12 1
15 42 M 172 65 HTN/DM 22 180 100 90 15 8300 248 27 0.6 200 0.4 4998 IV 42 27 46 33 55 1.28 0.94 1.36 22 1
16 40 M 180 78 x 24.1 100 70 98 12 8000 168 28 1.2 180 0.2 210 III 40 23 42 31 55 0.79 1.09 0.7 14 1
17 65 F 168 66 HTN/CVA/DM 23.4 170 100 76 14 4500 113 27 1.2 772 0.8 1098 IV 45 25 41 28 62 1.41 0.71 2.1 14 3
18 40 M 174 68 HTN/DM 22.4 170 100 76 13 4500 110 27 1.1 240 1.3 584 III 37 33 31 20 55 1.45 0.62 2.3 28 2
19 65 F 168 68 HTN/DM 24 170 120 84 13 14900 407 32 1.2 250 6.2 >2500 IV 42 26 41 35 55 1 0.88 1.1 30 1
20 60 F 154 54 HYPOTHYROIDISM 22.7 130 80 80 11 12300 120 14 1.2 130 0.5 70 III 28 26 52 23 60 0.94 1.25 0.75 12 2
21 58 M 172 72 COPD/HTN/CKD/DM 24.3 160 100 100 12 11500 128 101 4.8 210 0.5 1980 IV 42 26 42 23 60 1.06 0.5 2.1 21 3
22 60 M 168 70 HTN/DM/COPD/ 24.8 180 110 102 12 10000 348 33 1.07 260 0.2 2372 IV 41 31 50 16 60 1.06 0.62 1.7 20 2
23 60 F 150 55 HTN/DM 24.4 170 100 86 14 8200 120 32 0.9 180 0.2 475 III 40 21 20 20 60 0.96 0.68 1.4 12 1
24 45 M 155 80 OSA/DM 33.3 130 70 86 9.1 10500 92 24 1.2 210 0.7 1288 IV 30 28 45 20 60 1.21 0.84 1.4 24 3
25 65 F 165 60 x 22 120 80 86 12 14500 100 31 0.8 180 0.8 80 III 27 32 43 24 55 1.06 0.5 2.1 22 1
26 50 F 154 61 DM 25.7 130 90 86 12 10000 554 29 0.8 190 0.2 6.8 III 30 32 42 25 60 1.36 0.72 0.5 12 3
27 42 M 170 90 X 31.1 120 70 108 13 22000 150 38 0.3 193 0.8 280 III 43 33 50 31 55 0.84 1.4 0.6 8 2
28 56 M 175 95 HTN/T2DM 31 150 90 90 12 6800 250 25 1.2 180 0.2 442 III 40 24 36 22 58 0.87 0.96 0.9 16 1
29 60 F 154 62 DM 26.1 130 80 100 10 63 96 32 1.1 150 1.4 6523 III 43 21 38 26 60 1.21 0.84 1.4 24 2
30 65 F 160 58 HTN/T2DM 22.6 150 90 110 12 9000 298 18 1 218 0.2 1299 IV 40 28 50 39 60 1.06 1.12 0.9 22 3
31 60 F 156 55 HTN/T2DM 23.8 150 96 110 9.2 14500 132 26 1.1 180 0.4 83 III 40 25 46 29 60 0.62 1.08 0.5 10 3
32 80 F 156 56 HTN/DM 22.6 140 94 104 10 10000 147 24 0.7 146 0.2 1227 IV 43 28 55 34 55 0.94 1.25 0.75 12 2
33 62 F 160 80 HTN/T2DM 31.2 160 100 100 12 12500 240 30 1 230 0.6 778 III 42 26 48 30 60 0.84 1.4 0.6 8 3
34 58 M 170 85 HTN 29.4 150 90 90 8.2 6900 171 30 0.8 193 0.7 70 III 24 20 36 32 60 1.3 0.68 1.9 15 1
35 62 F 162 62 HTN/DM 23.6 160 100 98 12 5700 120 35 0.8 180 0.2 790 IV 42 30 45 32 60 1.3 0.68 1.9 15 2
36 78 F 160 63 DM2 24.6 110 70 96 13 9000 128 37 1 160 0.5 920 III 42 28 44 28 60 0.86 1.12 0.76 10 3
37 68 F 158 64 HTN/DM/HYPOTHYROIDISM 25.6 170 110 90 11 7800 186 32 0.6 190 1.1 1500 IV 40 25 45 30 60 0.74 1.32 0.6 14 1
38 52 M 170 80 HTN/T2DM 27.7 150 90 100 16 800 190 26 1.2 140 0.5 1020 III 42 25 45 30 58 0.82 0.82 1.4 12 3
39 65 F 160 66 HTN/DM 25.8 160 100 86 13 7200 160 32 1.2 180 0.2 7720 IV 44 22 38 28 60 1.21 1.21 1.4 22 3
40 60 F 165 68 HTN/T2DM 25 170 100 92 13 8200 396 26 1.2 210 0.8 1612 III 45 28 47 32 55 0.75 0.93 1.16 14 1
41 70 F 156 58 HTN 23.8 140 100 98 9.2 9000 110 32 0.5 150 0.2 620 III 40 26 50 34 54 0.94 1.25 0.75 11 2
42 60 F 160 72 HYPOTHYROIDISM 28.1 120 80 100 10 7900 160 39 0.7 180 0.4 220 IV 40 28 46 34 60 0.58 1.08 0.53 10 3
43 76 F 162 65 HTN/T2DM 24.7 160 100 98 11 7800 280 18 0.6 200 0.3 910 III 44 28 48 24 60 0.74 0.82 0.9 12 1
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44 70 M 165 72 HTN/DM 26.4 180 100 90 12 6000 80 58 1.2 120 0.6 460 III 50 50 50 36 58 1.07 1.2 1 2 2
45 65 F 168 68 HTN 24 168 100 94 13 6700 140 30 0.5 160 0.3 305 III 38 28 46 32 60 0.84 0.7 1.2 15 3
46 80 F 160 62 COPD/HTN 24.2 170 90 100 11 8000 120 34 0.6 190 0.3 250 III 42 30 40 28 58 0.96 0.6 1.6 13 1
47 65 M 176 82 HTN 26.4 170 110 100 13 5700 124 40 1 188 0.4 350 IV 40 21 40 22 60 0.45 0.5 0.9 12 3
48 80 M 170 70 HTN/DM 24.2 150 90 90 13 5600 195 33 1.1 120 1.2 291 IV 40 24 48 30 60 1.02 0.5 1.9 11 3
49 85 F 160 58 DM 22.6 110 80 90 11 6200 100 28 1.1 170 0.2 450 IV 42 30 46 31 60 1.2 0.62 1.9 12 2
50 85 F 160 52 DM 20.3 120 70 90 15 9000 122 40 0.7 228 0.3 430 III 40 28 35 21 60 0.63 0.74 0.7 11 1
